FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4252749471> ?p ?o ?g. }

• W4252749471 endingPage "3335" @default.
• W4252749471 startingPage "3327" @default.
• W4252749471 abstract "Recombinant human erythropoietin (rHuEPO) stimulates erythropoietic bone marrow cells and increases erythrocyte production. This prospective study was designed to evaluate the effects of rHuEPO on regeneration of erythropoiesis after allogeneic or autologous bone marrow transplantation (BMT). Seventeen centers participated in this randomized, double-blind, placebo-controlled multicenter trial. The randomization was performed centrally for each center and stratified according to allogeneic or autologous BMT and major ABO-blood group incompatibility. One hundred and six patients received rHuEPO after allogeneic BMT and 109 patients received placebo. After autologous BMT, 57 patients were treated with rHuEPO and 57 with placebo. Patients received either 150 IU/kg/day C127 mouse-cell-derived rHuEPO or placebo as continuous intravenous infusion. Therapy started after bone marrow infusion and lasted until independence from erythrocyte transfusions for 7 consecutive days with stable hemoglobin levels > or = 9 g/100 mL or until day 41. After allogeneic BMT, the reticulocyte counts were significantly higher with rHuEPO from day 21 to day 42 after BMT. The median time (95% confidence intervals) to erythrocyte transfusion independence was 19 days (range, 16.3 to 21.6) with rHuEPO and 27 days (range, 22.3 to > 42) with placebo (P < .003). The mean (+/- SD) numbers of erythrocyte transfusions until day 20 after BMT were 6.6 +/- 4.8 with rHuEPO and 6.0 +/- 3.8 with placebo. However, from day 21 to day 41, the rHuEPO-treated patients received 1.4 +/- 2.5 (median, 0) transfusions and the control group received 2.7 +/- 4.0 (median, 2) transfusions (P = .004). In the follow-up period from day 42 up to day 100, 2.4 +/- 5.6 transfusions were required with rHuEPO and 4.5 +/- 9.6 were required with placebo (P = .075). A multivariate analysis (ANOVA) showed that acute graft-versus-host disease (GVHD), major ABO-blood group incompatibility, age greater than 35 years, and hemorrhage significantly increased the number of transfusions. However, after day 20, rHuEPO significantly reduced the number of erythrocyte transfusions in these patient groups, as well as reducing incompatibility in the major ABO-blood group. For the whole study period, rHuEPO reduced the transfusion requirements in GVHD III and IV from 18.4 +/- 8.6 to 8.5 +/- 6.8 U (P = .05). After autologous BMT, there was no difference in the time to independence from erythrocyte transfusions and in the regeneration of reticulocytes. Marrow purging strongly increased the requirement for transfusions as well as the time to transfusion independence." @default.
• W4252749471 created "2022-05-12" @default.
• W4252749471 creator A5001564808 @default.
• W4252749471 creator A5037473051 @default.
• W4252749471 creator A5048288991 @default.
• W4252749471 creator A5049269263 @default.
• W4252749471 creator A5051760596 @default.
• W4252749471 creator A5056110674 @default.
• W4252749471 creator A5060864300 @default.
• W4252749471 creator A5068168305 @default.
• W4252749471 creator A5069015223 @default.
• W4252749471 creator A5088849954 @default.
• W4252749471 date "1994-11-15" @default.
• W4252749471 modified "2023-09-27" @default.
• W4252749471 title "A controlled trial of recombinant human erythropoietin after bone marrow transplantation" @default.
• W4252749471 doi "https://doi.org/10.1182/blood.v84.10.3327.bloodjournal84103327" @default.
• W4252749471 hasPublicationYear "1994" @default.
• W4252749471 type Work @default.
• W4252749471 citedByCount "0" @default.
• W4252749471 crossrefType "journal-article" @default.
• W4252749471 hasAuthorship W4252749471A5001564808 @default.
• W4252749471 hasAuthorship W4252749471A5037473051 @default.
• W4252749471 hasAuthorship W4252749471A5048288991 @default.
• W4252749471 hasAuthorship W4252749471A5049269263 @default.
• W4252749471 hasAuthorship W4252749471A5051760596 @default.
• W4252749471 hasAuthorship W4252749471A5056110674 @default.
• W4252749471 hasAuthorship W4252749471A5060864300 @default.
• W4252749471 hasAuthorship W4252749471A5068168305 @default.
• W4252749471 hasAuthorship W4252749471A5069015223 @default.
• W4252749471 hasAuthorship W4252749471A5088849954 @default.
• W4252749471 hasBestOaLocation W42527494711 @default.
• W4252749471 hasConcept C126322002 @default.
• W4252749471 hasConcept C141071460 @default.
• W4252749471 hasConcept C142724271 @default.
• W4252749471 hasConcept C168563851 @default.
• W4252749471 hasConcept C204243189 @default.
• W4252749471 hasConcept C204787440 @default.
• W4252749471 hasConcept C27081682 @default.
• W4252749471 hasConcept C2778248108 @default.
• W4252749471 hasConcept C2778534260 @default.
• W4252749471 hasConcept C2779703530 @default.
• W4252749471 hasConcept C2780007613 @default.
• W4252749471 hasConcept C2911091166 @default.
• W4252749471 hasConcept C71924100 @default.
• W4252749471 hasConcept C90924648 @default.
• W4252749471 hasConceptScore W4252749471C126322002 @default.
• W4252749471 hasConceptScore W4252749471C141071460 @default.
• W4252749471 hasConceptScore W4252749471C142724271 @default.
• W4252749471 hasConceptScore W4252749471C168563851 @default.
• W4252749471 hasConceptScore W4252749471C204243189 @default.
• W4252749471 hasConceptScore W4252749471C204787440 @default.
• W4252749471 hasConceptScore W4252749471C27081682 @default.
• W4252749471 hasConceptScore W4252749471C2778248108 @default.
• W4252749471 hasConceptScore W4252749471C2778534260 @default.
• W4252749471 hasConceptScore W4252749471C2779703530 @default.
• W4252749471 hasConceptScore W4252749471C2780007613 @default.
• W4252749471 hasConceptScore W4252749471C2911091166 @default.
• W4252749471 hasConceptScore W4252749471C71924100 @default.
• W4252749471 hasConceptScore W4252749471C90924648 @default.
• W4252749471 hasIssue "10" @default.
• W4252749471 hasLocation W42527494711 @default.
• W4252749471 hasOpenAccess W4252749471 @default.
• W4252749471 hasPrimaryLocation W42527494711 @default.
• W4252749471 hasRelatedWork W10435911 @default.
• W4252749471 hasRelatedWork W11525018 @default.
• W4252749471 hasRelatedWork W12158532 @default.
• W4252749471 hasRelatedWork W16378477 @default.
• W4252749471 hasRelatedWork W18673860 @default.
• W4252749471 hasRelatedWork W19185866 @default.
• W4252749471 hasRelatedWork W20746828 @default.
• W4252749471 hasRelatedWork W21619 @default.
• W4252749471 hasRelatedWork W6829174 @default.
• W4252749471 hasRelatedWork W9674236 @default.
• W4252749471 hasVolume "84" @default.
• W4252749471 isParatext "false" @default.
• W4252749471 isRetracted "false" @default.
• W4252749471 workType "article" @default.